Surgical treatment of non‐small cell lung cancer by stage

Abstract

Resection is the treatment of choice for stage I and II non-small cell lung carcinoma. The 5-year survival following resection is 72% in stage I carcinoma and 49% in stage II carcinoma. Resection alone or combined with radiation and/or chemotherapy is also indicated in some patients with stage IIIa disease. The 5 year survival with resection is 56% in tumors invading chest wall (T3N0), 30% in superior sulcus tumors, 30% in patients with N2M0 disease, and 36% in patients with tumors in proximity to carina. Surgery is of very limited value in patients with tumors invading the mediastinum and in patients with stage IIIb or stage IV disease. Details of case selection in each treatment category are presented.

Data from a national lung cancer registry contributes to improve outcome and quality of surgery: Danish results☆

“…The standards defining this indicator are very well documented [15,16], but interpretation of results is likewise difficult. It is a typical outcome indicator, where the results are influenced by multiple factors.…”

The Prognosis of Patients with Non-Small Cell Lung Cancer Found to Have Carcinomatous Pleuritis at Thoracotomy

“…2 However, it remains unelucidated whether or not there is any difference in survival after resection between patients who have a small amount of malignant pleural effusion and those who have positive lavage cytology. The standard treatment is still considered to be a surgical resection of the primary tumor in the latter patients.…”

“…At present, tumor resection is generally thought to be contraindicated. 2 In the present study, we retrospectively analyzed the above issue by conducting a questionnaire survey through the Japan Clinical Oncology Group (JCOG).…”

A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma

“…Some studies have suggested that radiotherapy at a total dose of 54 -64 Gy can eradicate microscopic residual cancer. [25][26][27][28][29][30][31][32] Furthemore, a nonrandomized study of patients with resected N2 cancer 35 indicates a survival advantage for the group of 88 patients who received postoperative radiotherapy. Ten randomized trials [5][6][7][8][9][10][11][12][13][14][15] involving a total of 1711 evaluable patients failed to demonstrate an improve- 11 Lung Cancer Study Group, 10 and the Van Houtte trial 9 ) used doses of 40 Gy, 50 Gy, and 60 Gy, respectively.…”